1 / 55

Inflammation , antiinflammatory products

Inflammation , antiinflammatory products. Prof. Dr. Borvendég János. Main topics of the presentation:. What does it mean inflammation? Synthtetic ( traditional) drugs with antiinflammatory actions. ( NSAIDs)

miriamm
Download Presentation

Inflammation , antiinflammatory products

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Inflammation,antiinflammatoryproducts Prof. Dr. Borvendég János

  2. Main topics of the presentation: • What does it mean inflammation? • Synthtetic ( traditional) drugs with antiinflammatory actions. ( NSAIDs) • Biological products with antiinflammatory actions / synthetic moleculs with tyrosine kinase inhibiting effects. Biosimilar products.

  3. Inflammation

  4. Biological function of inflammation • Inflammation (Latin, inflammatio) is part of thecomplexbiologicalresponseof body tissuestoharmfulstimuli, suchaspathogens, damagedcells, orirritants . • Itsprotectiveresponseinvolvingimmunecells, bloodvessels, and molecularmediators. • The function of inflammationis toeliminatetheinitialcause of cellinjury, clear out necroticcells and tissuesdamagedfromtheoriginalinsultandtheinflammatoryprocess, andtoinitiatetissuerepair.

  5. The classical signs of inflammation: • calor, dolor, rubor, tumor (heat, pain, redness and swelling) and loss of function. • Inflammation is a generic response,  innate immunity, as compared to  adaptive immunity, which is specific for each patogen.

  6. Too little/too much inflammation: • Too little inflammation : may lead to progressive tissue destruction by the harmful stimulus In contrast, • chronic inflammation may lead to a host of diseases, such as hay fever, periodontitis, atherosclerosis, rheumatoid arthritis, and even cancer (e.g., gallbladder carcinoma). • Inflammation is therefore normally closely regulated by the body.

  7. Phases of inflammation: • Acute phasesmediators of inflammation: histamine, serotonin, bradikinine, prostaglandins, leukotriens • Chronic phase mediators of inflammation : Interleukins 1,2,3 , TNF alpha , Interferon, PDFG( platelet derived grows factor)

  8. The outcome of inflammation can be: • beneficial( defence activity of the organism) or • deleterious (Chronic inflammation may lead to serious tissue destruction).

  9. Key factors in the process of inflammation: • lysosomal enzymes, (breaks down biomolecules,including peptides, nucleic acids, carbohydrates, and lipids). • prostaglandins ( produced by COX 1, and COX 2 enzymes), • leukotriens ( produced by lipoxigenase enzyme) • cytokines, hydroxyl radicals

  10. Therapeutic strategies • relief of pain, • reducing the inflammation • slowing or arrest the tissue damage • helptherepearmechanism.

  11. Anti inflammatory agents Classical products • NSAIDS ( Nonsteroidal anti-inflammatory drugs) • Glycocorticoids ( prednizolone, dexamethasone,triamcinolonetc.) • DMARDS ( Disease modifying anti rheumatic Drugs) like MTX( methotrexat), Chloroquine,Sulfasalazine.

  12. New antiinflammatory agents. • Biological products:-Anti TNF alfa drugs, Etanercept, Infliximab , Adalimumab etc.-IL (Interleukin inhibitors : IL-1,IL-6, IL-12,IL-17,IL-23 etc). • Tyrosine kinase inhibitors ( JAK)

  13. NSAIDS ( Nonsteroid Anti-inflammatory Agents): • Therapeutic effects: anti-inflammatory analgesic antipyretic platelet effect • Other effects of anti-inflammatory agents:Inhibits leukocyte migration, decreases oxygen radical production inhibit lymphocyte function • Side effects: gastrointstinal haemorrhage, upper GI bleeding, intolerance , vomiting tinnitus,

  14. Mechanism of action of NSAIDs • Cyclooxygenase (COX), officiallyknownasprostaglandin-endoperoxidesynthase (PTGS), is an enzyme (specifically, a family of isozymes, that is responsibleforformation of prostanoids, includingthromboxane and prostaglandinssuchasprostacyclin. • There are two isozymes of COX encoded by distinct gene products: a constitutiveCOX-1and an inducibleCOX-2,ensymewhich differ in their regulation of expression and tissue distribution. .

  15. Selevtive COX-2 inhibitors ? •  The impetus for development of selective COX-2 inhibitors was the adverse gastrointestinal side effects of nonselective NSAIDs. •  After a short time, it became evident that there was a fivefold higher risk of myocardial infarction in the rofecoxib (selective COX2 inhib.) group compared to the group that received naproxen

  16. NSAID drugs • Products: aspirin diclofenac naproxen, ibuprofen, meloxicam, piroxicam, sulindac indometacin etc.COX 2 selective : Celecoxib, Rofecocib ( withdrown) • Chemical structures: acetyl salicylic acid propionic acid derivatives, phenylpropionic acid , iodole derivatives naphthylpropionic acid oxicams

  17. Tyrosine kinase inhibitors. • Protein kinases mediate protein phosphorylation, which is a fundamental component of cell signalling, with crucial roles in most signal transduction cascades: from controlling cell growth and proliferation to the initiation and regulation of immunological responses. • Janus kinase (JAK), mitogen-activated protein kinase (MAPK) and spleen tyrosine kinase (Syk) inhibitors. JAK3 expression, as well as STAT-4, -5 and -6 expression, was increased in the synovium of patients with RA, This finding was confirmed in other studies, leading to selective inhibition of JAK kinases becoming a therapeutic strategy for the treatment of RA, as well as other inflammatory-mediated diseases

  18. Registered tyrosin kinase inhibitor: • TofacitinibJAK3 , JAK2 , JAK1 inhibitor (Pfizer ) syntheticsmallmoleculfororalteatment. • FDA-approved (November 2012). EMA( 2016) • Indications: RheumatoidarthritisPsoriasisInflammaroryBowelDiseases • To date, the US FDA has approved about 30small-molecule kinase inhibitors, halfof which were approved in the past 5years. 

  19. Baricitinib JAK1/JAK2 inhibitor (EliLilly) • EMA-approved 2017.syntheticsmallmoleculfororalteatment.ofpatients with moderate to severe rheumatoid arthritis when standard treatment with disease-modifying anti-rheumatic drugs has not worked well enough or if patients cannot tolerate them.

  20. Biological medicinal products

  21. Biologicalmedicinalproducts(EMA definition) Medicinalproductscontainingbiotechnology-derivedproteinsasactivesubstance, immunologicalssuchasvaccines, blood-derivedproducts, monoclonalantibodies, etc.

  22. The significance of biologicalproducts (BP) • The majority of BP-s is important medicine, • The price of the innovator BP-s is extremely high, • To curb the healthcare spending is in the interest of the society and also of the insurance agencies • The potential for BP manufacturers is great (currently $US 30 bn annual sales in the US)

  23. Major kinds of biopharmaceuticals: Importantendogenesligands of theorganism: Bloodfactors (Factor VIII and IX) Tissueplasminogenactivator (thrombolyticagens) Hormones: insulin, growthhormone, gonadotropins (FSH) Haematopoieticfactors: erythropoitin, colonystimulatingfactors

  24. Major kinds of biopharmaceuticals: Monoclonal antibodies (mab) blocking the activities of: Tu. Necrosis Factor (TNFalfa), Interferons, Interleukins (ILs), enzymes Additional products (therapeutic enzymes, vaccins ,etc.)

  25. Biopharmaceuticals ProducedbyrecombinantDNA technic: 1.) Substances ≈ identicaltothe body’s ownkeysignallingproteins. (e.g. insulin, growthhormone) 2.) Monoclonalantibodies (toblockthefunction of anygivensubstance, enzymes, specificcelltypes) 3.) Receptor constructs (fusionproteins) (receptor linked to immunglobulin)

  26. Production of biologicalproducts:

  27. Possibledifferencesinthemanufacturingprocess:

  28. Main indications of the biological products today • Chronic inflammatory diseases: • Rheumatoid Arthritis, ostheoarthritis, spondylarthritis, chronic inflammatory boweldiseases Psoriasis. • Other incations for diseases in: oncology, haematology endocrinology, neurology

  29. Biologicalmedicinesforthetreatment of inflammatoryconditions etanercepthuman fusion protein → TNFα (Enbrel) antagonist • RheumatoidArthitis (RA) •ankylosingspondylitis • psoriasis adalimumabmab→ TNFα (Humira) • RA •ankylosingspondylitis • Crohn’s disease (chronicbowelinflammation) •psoriasis

  30. Biologicalmedicinesforthetreatment of inflammatoryconditions Infliximabchimericmab → TNFα (Remicade) • RA •ankylosingspondylitis • Crohn’s disease •psoriasis

  31. Biologicalmedicinesforthetreatment of inflammatoryconditions rituximabchimericmab → CD20 protein or B cells (Rituxan) • RA tocilizumabhumanisedmab→ IL-6 (Actemra) • RA anakinra→ blocks IL-1 („mastercytokine”) (Kinaret) abatacept → blocksthefunction of a type of white (Orencia) bloodcell (Tcells)

  32. Biologicalproductsinoncology trastuzumab(Herceptin) → HER 2 breastcc. rituximab (MabThera) → anti-CD20 ab B-cellmalignancies (lymphoma) bevacizumab→ VEGF angiogenesis inhibitor

  33. Biopharmaceuticalsaredifferentfromtraditionalmedicines: • Complexmanufacturingprocess • Highmolecularweight • Complex 3-D sturcture • Difficulttocharacterize • Instability -*- • Immunogenicity

  34. Factorswhichmaychangethestructure of theproteins: Chemically: oxidation deamidation disulfide shuffling racemisation Physically: unfolding misfolding aggregation precipitation fragmentation

  35. The complexity of the BP which has a great impact of characterising physicochemically/biologically of their structure/properties • BP have different levels of complexity • The methods and extent of analytical studies must have the ability to characterize in depth the BP in question • The complexity and extent at the subsequent level (pharm. tox. clinical) should be determined on case by base basis, taking account the results gained from the initial physicochemical/biological analysis.

  36. Factorswhichmayinfluencetheimmunogenicity of biologicalproducts: Non-product related factors: underlying disease genetic background immun status co-medications Product related factors: source of proteins protein structure glycosilation impurity stability (degradation products) aggregation formulation/excipiens Application related factors: route of administration dose-dose internal duration of treatment

  37. Types of reproduced drugs: • Generic products ( bioequivalent dugs) • Biosimilar products

  38. What is a genericmedicine? - containsthesameactivesubstance of samequalityasthereferencemedicine, but - itsappearance (color/shape), - theinactiveingredients (excipients), - themanufacturingprocesscan be different, but - theinnovator and thegenericproduct must be bioequivalent (in PK parameters: AUC, Cmax) - efficacy / safetyhaveto be equal.

  39. Generic drugs • They are equivalent with the original product in: • chemical structures, • bioequivalent in: • Pharmaco-kinetic properties, • Pharmacodynamic, and • Therapeutic effiects and in safety ( advers reactions)

  40. BiosimilarProduct:(EMA definition) Biosimilar, orsimilarbiologicalmedicalproduct is „a newbiologicalproductsimilartoa licenced reference (biological) medicinalproduct”. US/FDA: „follow-on protein product”

  41. Biosimilarity: - A biologicalmedicine is biosimilarto a referencebiologicalmedicineifsimilarin: - quality - efficacy - safety- Biosimilar and referencebiologicalmedicinesaresimilarbutnotidentical

  42. SimilarBiologicalMedicinalProduct (SBMP) Basic principles: - SPMP-s are not generic productsThe „standard generic approach” is not acceptable due to the complexity of biological/biotechnology-derived aproducts. - „Similar biological approach” depends on the state of art of analytical procedures.

  43. SimilarBiologicalMedicinalProduct (SBMP) Basic principles (cont.): They regulatory requirements are guided (on case by case basic) by the: - extent of the physicochemical/biological characterisation of the product, - nature or possible changes in the quality/structure of the biological product due the changes in the manufacturing process (and their unexpected outcomes) - clinical/regulatory experiences with the particular class of the product in question

  44. Clinicalstudieswithbiosimilarproducts: • Requirements depend on- type/properties of the SBMP- data gained from physicochemical and preclinical analyses- therapeutic indication • Stepwise procedure- PK- PD- Therapeutic equivalence studies

  45. Consequencies of immuneresponse: • Safety (allergy, anaphylaxis) • Efficacy:- loss (due to neutralising antibodies)- enhancement • Activity of endogenous (similar) proteins- loss (neutralisation) • PK clearance:- increase- decrease -*- Extent and significance of immune responseto clinical efficacy/safety!?

  46. The most important patent expirations: somatropin recombinant insulin erythropoetin G-CSF tPA IL-2 IFN-alfa 2b IFN-gamma-1b Streptokinase - * - rituximab trastuzumab

  47. Is it simple to make a biosimilar?

  48. Are these animals biosimilar?

  49. Are these animalsbiosimilar?

  50. Hurdlesinthefastergrowth of biosimilar market • Biosimilarsarespecificproducts • Regulationsfor marketing approvalaremuchstricterthanthoseforconventionalgenerics • The requiredcapitalinvestment and cost of manufacturingaremuchhigherforbiosimilars and theprobability of succesfullaunch is lowerthanthoseforchemical-basedgenerics

More Related